CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of pancreatic cancer.
  
  OVERVIEW OF ACTIVITY
  Pancreatic cancer is the fourth most common cause of cancer-related death among men and women in the United States. The overwhelming majority (approximately 90%) of pancreatic cancer cases are ductal adenocarcinoma. Unfortunately, many patients diagnosed with pancreatic adenocarcinoma (PAD) do not exhibit disease-specific symptoms until the cancer has reached an advanced stage, so for all stages of PAD the combined 1-year survival rate is approximately 29% and the 5-year rate is 2% to 9%. Published clinical trial results have led to the emergence of new therapeutic targets and regimens, and the poor clinical course for many patients with progressive PAD mandates the investigation of even more new approaches. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Pancreatic Cancer Update presents one-on-one discussions with leading gastrointestinal oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.
  
  LEARNING OBJECTIVES

  • Develop an evidence-based strategy for the treatment of resectable or borderline-resectable pancreatic cancer, exploring the role of neoadjuvant and adjuvant therapy.
  • Consider patient age, performance status and other clinical and logistic factors in the selection of systemic therapy for patients with locally advanced or metastatic pancreatic cancer.
  • Recall available Phase III data documenting the efficacy and safety of olaparib maintenance therapy after first-line platinum-based chemotherapy for patients with newly diagnosed PAD and a germline BRCA mutation.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens in the management of locally advanced or metastatic pancreatic cancer.
  • Describe the rationale for testing patients with metastatic pancreatic cancer for mutations in DNA repair genes (eg, BRCA1, BRCA2, PALB2), and advise individuals found to harbor these genetic abnormalities about participation in clinical trials evaluating PARP inhibition.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: 
  
  Michael J Pishvaian, MD, PhD
  Associate Professor
  Department of Gastrointestinal Medical Oncology
  Co-Director for Clinical Research
  Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Merck, RenovoRX, Sirtex Medical Ltd; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Perthera Inc, RenovoRX, Sirtex Medical Ltd; Ownership Interest: Perthera Inc; Speakers Bureau: Sirtex Medical Ltd.
  
  Talia Golan, MD
  Medical Director
  Phase I Program and Sheba Pancreatic Cancer Program
  Sheba Medical Center
  Ramat Gan, Israel
  
  Advisory Committee: AbbVie Inc, Bayer HealthCare Pharmaceuticals, Merck Sharp & Dohme Corp, Teva Oncology; Consulting Agreement: AbbVie Inc; Contracted Research and Speakers Bureau: AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme Corp.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: January 2020
  Expiration date: January 2021